TY - JOUR
T1 - Phenotype-specific treatment of heart failure with preserved ejection fraction
AU - Shah, Sanjiv J.
AU - Kitzman, Dalane W.
AU - Borlaug, Barry A.
AU - Van Heerebeek, Loek
AU - Zile, Michael R.
AU - Kass, David A.
AU - Paulus, Walter J.
N1 - Funding Information:
Dr Shah is supported by grants from the National Institutes of Health (RO1 HL107577 and RO1 HL127028). Dr Borlaug is supported by funding from the National Heart Lung and Blood Institute (NHLBI) Heart Failure Research Network (U10 HL110262-01) and research grants of Aires Pharmaceuticals, Medtronic, Teva, and GSK. Dr Kitzman is supported by National Institute of Health grants R01AG18915 and P30AG21332 and by the Kermit Glenn Phillips II Chair in Cardiovascular Medicine. Dr van Heerebeek is supported by grants from the European Commission (FP7-Health-2010; MEDIA-26140) and from CardioVasculair Onderzoek Nederland (CVON), Dutch Heart Foundation, The Netherlands (RECONNECT). Dr Zile receives research support from NHLBI, Veterans Administration, Bayer, CVRx, Medtronic, Novartis. Dr Kass is supported by RO1 HL119012 and HL114910. Dr Paulus is supported by grants from the European Commission (FP7-Health-2010; MEDIA-26140) and from CVON, Dutch Heart Foundation, The Netherlands (ARENA, RECONNECT, EARLY-HFPEF).
Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/7/5
Y1 - 2016/7/5
N2 - Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
AB - Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.
KW - diastole
KW - heart failure
KW - heart failure, diastolic
KW - phenotype
KW - therapeutics
KW - ventricular function, left
UR - http://www.scopus.com/inward/record.url?scp=84977271048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977271048&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.116.021884
DO - 10.1161/CIRCULATIONAHA.116.021884
M3 - Article
C2 - 27358439
AN - SCOPUS:84977271048
SN - 0009-7322
VL - 134
SP - 73
EP - 90
JO - Circulation
JF - Circulation
IS - 1
ER -